BeiGene
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019.
Link from a Wikipage to another Wikipage
primaryTopic
BeiGene
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019.
has abstract
BeiGene is a biotechnology com ...... ell lymphoma in November 2019.
@en
founded by
founding year
revenue ($)
type
Link from a Wikipage to an external page
Wikipage page ID
64,754,591
page length (characters) of wiki page
Wikipage revision ID
1,022,602,108
Link from a Wikipage to another Wikipage
founded
in Beijing, China
@en
founder
logo
@en
name
BeiGene
@en
operating income
revenue
traded as
@en
NASDAQ:BGNE
@en
SEHK:6160
@en
type
website
wikiPageUsesTemplate
subject
comment
BeiGene is a biotechnology com ...... ell lymphoma in November 2019.
@en
label
BeiGene
@en
sameAs
wasDerivedFrom
homepage
isPrimaryTopicOf
name
BeiGene
@en